Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19/BCMA-UCAR-T Cells in Refractory Autoimmune Diseases
NCT07558850Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2026
- Primary completion
- Jan 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of KN3601 in rheumatoid arthritis (RA), dermatomyositis (DM), systemic lupus erythematosus (SLE) and 1 more, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Dose-Limiting Toxicity at 48 weeks and Treatment Emergent Adverse Events at 48 weeks. Started May 2026; status: recruiting.
02
Drugs
KN3601
03
Conditions
rheumatoid arthritis (RA)dermatomyositis (DM)systemic lupus erythematosus (SLE)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07558850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07558850.